ATE324877T1 - Behandlung von metastatischer krankheit - Google Patents

Behandlung von metastatischer krankheit

Info

Publication number
ATE324877T1
ATE324877T1 AT00955687T AT00955687T ATE324877T1 AT E324877 T1 ATE324877 T1 AT E324877T1 AT 00955687 T AT00955687 T AT 00955687T AT 00955687 T AT00955687 T AT 00955687T AT E324877 T1 ATE324877 T1 AT E324877T1
Authority
AT
Austria
Prior art keywords
treatment
metastatic disease
compounds
metastatic
disease
Prior art date
Application number
AT00955687T
Other languages
English (en)
Inventor
Michael Scott Kinch
Katherine E Kilpatrick
Nicole D Zantek
Patrick W Hein
Original Assignee
Purdue Research Foundation
Glaxo Group Ltd
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22529456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324877(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Research Foundation, Glaxo Group Ltd, Univ North Carolina filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of ATE324877T1 publication Critical patent/ATE324877T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00955687T 1999-08-17 2000-08-17 Behandlung von metastatischer krankheit ATE324877T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14925899P 1999-08-17 1999-08-17

Publications (1)

Publication Number Publication Date
ATE324877T1 true ATE324877T1 (de) 2006-06-15

Family

ID=22529456

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00955687T ATE324877T1 (de) 1999-08-17 2000-08-17 Behandlung von metastatischer krankheit

Country Status (10)

Country Link
EP (2) EP2289940A3 (de)
JP (2) JP2003516930A (de)
AT (1) ATE324877T1 (de)
AU (1) AU6784400A (de)
CA (1) CA2380888A1 (de)
DE (1) DE60027768T2 (de)
DK (1) DK1242060T3 (de)
ES (1) ES2261230T3 (de)
PT (1) PT1242060E (de)
WO (1) WO2001012172A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
CN102805868A (zh) 2000-03-31 2012-12-05 普渡研究基金会 用配体-免疫原缀合物治疗的方法
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
EP1225233A3 (de) * 2001-01-23 2003-01-08 Amsterdam Support Diagnostics B.V. Mittel und Methoden für die Abschätzung einer Behandlung
CA2369183A1 (en) * 2001-01-23 2002-07-23 Amsterdam Support Diagnostics B.V. Means and methods for treatment evaluation
EP1298221A1 (de) * 2001-09-28 2003-04-02 PrimaGen Holding B.V. Mittel und Methoden für die Abschätzung einer Behandlung
JP2005523878A (ja) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
EP1474535A4 (de) * 2002-02-15 2006-11-08 Millennium Pharm Inc Verfahren und zusammensetzungen zur behandlung von mit aids und hiv in zusammenhang stehenden erkrankungen unter verwendung der moleküle 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784 oder 2045
WO2005051307A2 (en) * 2003-11-20 2005-06-09 Medimmune, Inc. Epha2 agonistic monoclonal antibodies and methods of use thereof
ES2377720T3 (es) * 2002-05-10 2012-03-30 Purdue Research Foundation Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
WO2003099313A1 (en) 2002-05-23 2003-12-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target
AU2003900541A0 (en) * 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
AU2004210463B2 (en) * 2003-02-07 2009-07-16 Ludwig Institute For Cancer Research Limited Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis
JP2006524693A (ja) * 2003-04-11 2006-11-02 メディミューン，インコーポレーテッド ＥｐｈＡ２および非腫瘍性過増殖性細胞障害
AU2004230539A1 (en) * 2003-04-11 2004-10-28 Medimmune, Llc EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
WO2004101764A2 (en) 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
WO2005016381A2 (en) * 2003-07-21 2005-02-24 Medimmune, Inc. Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
WO2006023420A2 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
AU2006210460B2 (en) 2005-02-04 2012-04-05 Macrogenics West, Inc. Antibodies that bind to EphA2 and methods of use thereof
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
NZ574215A (en) 2006-07-18 2012-07-27 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
WO2008033966A2 (en) 2006-09-12 2008-03-20 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
EP2066346B1 (de) 2006-09-12 2019-07-03 AlphaVax, Inc. Für il-12 kodierende alphavirusreplikationspartikel als immunologische hilfsstoffe
WO2008058035A1 (en) 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
WO2009028639A1 (ja) * 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6729917B2 (ja) * 2016-08-19 2020-07-29 国立大学法人 東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体
EP3830109A4 (de) 2018-08-03 2022-05-18 Uab Research Foundation Verfahren und zusammensetzungen für eine alphavirus-impfung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2129454T3 (es) 1991-08-22 1999-06-16 Becton Dickinson Co Procedimientos y composiciones de tratamientos de cancer y pronostico de reacciones a los indicados tratamientos.
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
WO2000030673A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders

Also Published As

Publication number Publication date
WO2001012172B1 (en) 2001-08-16
EP1242060A1 (de) 2002-09-25
JP2007306938A (ja) 2007-11-29
JP2003516930A (ja) 2003-05-20
PT1242060E (pt) 2006-08-31
CA2380888A1 (en) 2001-02-22
DE60027768T2 (de) 2007-04-05
EP1242060B1 (de) 2006-05-03
EP1242060A4 (de) 2003-09-24
ES2261230T3 (es) 2006-11-16
DK1242060T3 (da) 2006-08-21
EP2289940A3 (de) 2011-09-21
EP2289940A2 (de) 2011-03-02
AU6784400A (en) 2001-03-13
DE60027768D1 (de) 2006-06-08
WO2001012172A1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
ATE324877T1 (de) Behandlung von metastatischer krankheit
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
ATE265456T1 (de) 2-amino-6-anilino-purine und deren verwendung als arzneimittel
TR200200928T2 (tr) 2-pirazolin-5-on terkipleri
EP1140840A4 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
EP1231914A4 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
BR9814361A (pt) Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
CY1106816T1 (el) 1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
NO2010002I2 (no) Toceranibfosfat.
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
ATE305300T1 (de) Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
CA2367704A1 (en) Pyrazolobenzodiazepines as cdk2 inhibitors
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
BR0209149A (pt) Ftalazinonas
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
TR200200260T2 (tr) N-desmetilzopiklonlarının üretim ve kullanım yöntemleri
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
DE60019894D1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242060

Country of ref document: EP

RZN Patent revoked